Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH
Portfolio Pulse from
Grace Therapeutics announced successful results from its Phase 3 STRIVE-ON safety trial for GTx-104, an injectable formulation of nimodipine for aSAH patients. The trial met its primary endpoint, showing clinical benefits over oral nimodipine. An NDA submission is expected in the first half of 2025.
February 10, 2025 | 1:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Grace Therapeutics' Phase 3 trial for GTx-104 met its primary endpoint, indicating clinical benefits over oral nimodipine. This success paves the way for an NDA submission in 2025, potentially boosting the company's market position.
The successful Phase 3 trial results for GTx-104 demonstrate a significant clinical benefit over existing oral treatments, which is a positive development for Grace Therapeutics. This success is likely to enhance investor confidence and could lead to a stock price increase as the company prepares for an NDA submission in 2025.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100